Compare MCB & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCB | SVRA |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2017 | 2009 |
| Metric | MCB | SVRA |
|---|---|---|
| Price | $98.48 | $5.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $98.67 | $7.33 |
| AVG Volume (30 Days) | 137.7K | ★ 2.0M |
| Earning Date | 04-21-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 11.64 | N/A |
| EPS | ★ 2.92 | N/A |
| Revenue | ★ $11,053,000.00 | N/A |
| Revenue This Year | $37.22 | N/A |
| Revenue Next Year | $14.75 | $430.87 |
| P/E Ratio | $34.60 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $64.66 | $2.26 |
| 52 Week High | $102.04 | $7.01 |
| Indicator | MCB | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 42.96 |
| Support Level | $86.38 | $5.47 |
| Resistance Level | $102.04 | $6.15 |
| Average True Range (ATR) | 2.49 | 0.26 |
| MACD | -0.16 | -0.10 |
| Stochastic Oscillator | 49.34 | 11.11 |
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).